Travere Therapeutics, Inc. TVTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$88.54M+47.6% | -$169.06M+25.4% | -$226.71M+29.5% | ||
| $73.15M+20.4% | $60.74M+11.1% | $54.7M+9.1% | $50.15M+7.9% | $46.48M+6.7% | ||
| $49.52M+10.4% | $44.87M+5.3% | $42.62M+8.2% | $39.38M+1.9% | $38.65M+4.7% | ||
| —— | —— | —— | —— | -$160.66M+32.3% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $78.97M-45.3% | $144.36M+0.5% | $143.67M+3.0% | ||
| —— | —— | $74.52M+73.9% | $42.86M+130% | $18.65M+5,094% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.